drugset / Trial / NCT04634825
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 2 study of enoblituzumab combined with either retifanlimab or tebotelimab administered as first-line treatment to patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Timeline
- Start
- 2021-03-17
- Primary completion
- 2022-07-29
- Completion
- 2022-07-29
Outcome
Outcome not reported
Stopped: “Based on internal review of safety data”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enoblituzumab | Monoclonal antibody | 15 mg/kg | — |
| Subject | Retifanlimab | Monoclonal antibody | 375 mg | — |
| Subject | Tebotelimab | Protein / enzyme biologic | 600 mg | — |